Dermatology

Investigators added that the meaning of each laboratory marker is dependent on the drug that is being used for treatment.

The drug is approved for adults and pediatric patients 12 years and older after the failure of 1 or 2 lines of systemic therapy.

The approval follows recent phase 3 trial data showing significant improvement in patient-reported outcomes for the treatment of atopic dermatitis.

The treatment was approved for adult patients with plaque psoriasis in 2018.

The regulatory setback is regarding a manufacturing facility concern not associated with the investigative drug, according to the company.

In this episode of Derm Discussions, vitiligo expert John Harris, MD, PhD, discusses new tactics and therapeutic options in treating inflammatory skin disorders like vitiligo, alopecia areata, and atopic dermatitis.

The wound care matrix is composed of hydrolyzed fish collagen infused with cod liver oil and other plant-derived oil and wax to aid in the natural wound healing process.

Investigators hope that the emerging method of managing these atopic diseases can help remove racial and socioeconomic barriers to care.

Investigators believe their study shows the efficacy and safety of the 2 biologic agents, which are known to have anti-inflammatory and immunosuppressant qualities.

Investigators believe the treatment strategy can go on to treat other “difficult-to-treat” areas of the body such as palms, elbows, and lips.

A new study shows that research and educational resources are greatly lacking regarding skin color and dermatology education.

Though investigators called for more research on the biologic, recent data showed patients treated with bimekizumab recorded improved skin pain when compared to placebo and adalimumab.

Investigators write that methods such as dermatoscopy can result in early recognition of unstable patches and lead to appropriate medical treatment for patients with vitiligo.

A new study showed about half of all vitiligo patients from a care system were burdened with the sleeping disorder.

According to a claims analysis, sunburn was also commonly diagnosed in female and young patients.

The prevalence of striae distensae was notably higher in psoriasis than atopic dermatitis.

Brett King, MD, PhD, encourages dermatologists to wait for more clinical data before making any assumptions on the drug class' safety and selectivity.

Brett King, MD, PhD, compares the efficacy of JAKs with biologics in the atopic dermatitis setting.

Experts in dermatology discuss the clinical presentation of atopic dermatitis, common comorbidities associated with the disease, and its impact on patient quality of life.

Margaret Bobonich, DNP, FNP-C, DCNP, FAANP, and Douglas DiRuggiero, DMSc, PA-C, provide an overview of atopic dermatitis including prevalence, age of onset, and diagnosis.

Brett King, MD, PhD, provides an overview of JAK inhibitors and their interaction with the JAK-STAT pathway.

Studies are needed to determine the best treatment regimen for these patients.

Treatment was associated with reductions in IGA scores as well as inflammatory and non-inflammatory lesion counts.

The selective topical PDE4 inhibitor demonstrated rapid improvements in IGA and EASI scores and high tolerability in pediatric populations.

On the latest Derm Discussions, Brett King, MD, PhD, joins Brad Glick, DO, to discuss the potential of the JAK inhibitor class for dermatology.